北欧国家注意缺陷多动障碍药物的使用：一项基于人群的比较研究。
Use of ADHD drugs in the Nordic countries: a population-based comparison study.
机构信息
Centre of Public Health Sciences, University of Iceland, Reykjavík, Iceland.
出版信息
Acta Psychiatr Scand. 2011 May;123(5):360-7. doi: 10.1111/j.1600-0447.2010.01607.x. Epub 2010 Sep 23.
OBJECTIVE
To compare national use of attention-deficit/hyperactivity disorder (ADHD) drugs between five Nordic countries.
METHOD
A population-based drug utilisation study based on nationwide prescription databases, covering in total 24 919 145 individuals in 2007. ADHD drugs defined according to the World Health Organization Anatomic Therapeutic Chemical classification system as centrally acting sympathomimetics (N06BA).
RESULTS
The 2007 prevalence of ADHD drug use among the total Nordic population was 2.76 per 1000 inhabitants, varying from 1.23 per 1000 in Finland to 12.46 per 1000 in Iceland. Adjusting for age, Icelanders were nearly five times more likely than Swedes to have used ADHD drugs (Prev.Ratio = 4.53, 95% CI: 4.38-4.69). Prevalence among boys (age 7-15) was fourfold the prevalence among girls (Prev.Ratio = 4.28, 95% CI: 3.70-4.96). The gender ratio was diminished among adults (age 21 +) (Prev.Ratio = 1.24, CI: 1.21-1.27).
CONCLUSION
A considerable national variation in use of ADHD drugs exists between the Nordic countries.
目的
比较五个北欧国家对注意缺陷多动障碍（ADHD）药物的使用情况。
方法
一项基于全国处方数据库的基于人群的药物使用研究，涵盖了 2007 年总共 24919145 人。ADHD 药物根据世界卫生组织解剖治疗化学分类系统定义为中枢作用拟交感神经药（N06BA）。
结果
2007 年北欧总人口 ADHD 药物使用率为每千人 2.76 人，芬兰为每千人 1.23 人，冰岛为每千人 12.46 人。调整年龄后，冰岛人使用 ADHD 药物的可能性几乎是瑞典人的五倍（流行率比=4.53，95%CI：4.38-4.69）。7-15 岁男孩的患病率是女孩的四倍（流行率比=4.28，95%CI：3.70-4.96）。成年人（21 岁及以上）的性别比降低（流行率比=1.24，CI：1.21-1.27）。
结论
北欧国家之间 ADHD 药物的使用存在相当大的国家差异。
Zotero 插件